Should I buy or sell Hillstream BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HILS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HILS, but not buy additional shares or sell existing shares. View HILS analyst ratings or view top-rated stocks .

How have HILS shares performed in 2024?

Hillstream BioPharma's stock was trading at $0.2305 at the beginning of 2024. Since then, HILS shares have increased by 63.6% and is now trading at $0.3770. View the best growth stocks for 2024 here .

When did Hillstream BioPharma IPO?

Hillstream BioPharma (HILS) raised $21 million in an initial public offering on Wednesday, January 12th 2022. The company issued 3,750,000 shares at a price of $5.00-$6.00 per share.

How do I buy shares of Hillstream BioPharma?

Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HILS

Hillstream BioPharma (HILS) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)

Free HILS Stock Alerts

$0.38

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.37
▼
$0.39
50-Day Range: $0.23
▼
$0.47
52-Week Range: $0.19
▼
$2.65

Volume: 38,597 shs
Average Volume: 1.39 million shs
Market Capitalization: $6.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Hillstream BioPharma alerts:

Ad American Alternative

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

CLICK HERE TO GET YOUR GUIDE NOW

About Hillstream BioPharma Stock (NASDAQ:HILS)

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

HILS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HILS Stock News Headlines

April 17, 2024 | morningstar.com

Hill & Smith PLC HILS

April 13, 2024 | americanbankingnews.com

Hillstream BioPharma (NASDAQ:HILS) Stock Price Down 6.9%

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

October 31, 2023 | morningstar.com

Kiromic BioPharma Inc Ordinary Shares KRBP

September 22, 2023 | finance.yahoo.com

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

September 21, 2023 | finance.yahoo.com

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

September 11, 2023 | finance.yahoo.com

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

September 8, 2023 | finance.yahoo.com

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

August 30, 2023 | benzinga.com

Hillstream – Drug Maker Licenses Critical New Technology In Fight Against Cancer

August 25, 2023 | seekingalpha.com

NMTRQ 9 Meters Biopharma, Inc.

August 9, 2023 | finance.yahoo.com

Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023

July 20, 2023 | finance.yahoo.com

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215

July 10, 2023 | finance.yahoo.com

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

July 6, 2023 | finance.yahoo.com

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

June 9, 2023 | finance.yahoo.com

HILS - Hillstream BioPharma, Inc.

May 15, 2023 | finance.yahoo.com

Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

May 4, 2023 | finanznachrichten.de

Hillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common Stock

May 2, 2023 | finance.yahoo.com

Hillstream BioPharma Announces Closing of Public Offering of Common Stock

May 2, 2023 | finance.yahoo.com

Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences

April 29, 2023 | benzinga.com

Hillstream BioPharma Stock (NASDAQ:HILS), Short Interest Report

April 28, 2023 | finanznachrichten.de

Hillstream BioPharma, Inc.: Hillstream BioPharma Announces Proposed Public Offering

April 28, 2023 | marketwatch.com

Hillstream BioPharma Shares Slide Premarket on Stock Offering >HILS

April 28, 2023 | investorplace.com

Why Is Hillstream BioPharma (HILS) Stock Down 57% Today?

April 28, 2023 | finanznachrichten.de

Hillstream BioPharma, Inc.: Hillstream BioPharma Announces Pricing of Public Offering

April 27, 2023 | finance.yahoo.com

Hillstream BioPharma Announces Pricing of Public Offering

April 27, 2023 | finance.yahoo.com

Hillstream BioPharma Announces Proposed Public Offering

See More Headlines

Receive HILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HILS
CUSIP: N/A
CIK: 1861657
Web: www.hillstreambio.com
Phone: 908-955-3140
Fax: N/A
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,470,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -188.44%
Return on Assets: -149.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.01
Quick Ratio: 3.01

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 0.79

Miscellaneous

Outstanding Shares: 17,603,000
Free Float: 12,280,000
Market Cap: $6.64 million
Optionable: Not Optionable
Beta: 3.08

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Randy D. Milby MBA (Age 69)
Pres, Chairman & CEO
Comp: $471.94k
Mr. Sireesh Appajosyula Pharm.D. (Age 47)
COO & Director
Comp: $64.96k
Mr. Thomas P. Hess CPA (Age 59)
MBA, Chief Financial Officer

Key Competitors

View All Competitors

HILS Stock Analysis - Frequently Asked Questions

Should I buy or sell Hillstream BioPharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" HILS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HILS, but not buy additional shares or sell existing shares.
View HILS analyst ratings or view top-rated stocks.
How have HILS shares performed in 2024?: Hillstream BioPharma's stock was trading at $0.2305 at the beginning of 2024. Since then, HILS shares have increased by 63.6% and is now trading at $0.3770.
View the best growth stocks for 2024 here.
When did Hillstream BioPharma IPO?: Hillstream BioPharma (HILS) raised $21 million in an initial public offering on Wednesday, January 12th 2022. The company issued 3,750,000 shares at a price of $5.00-$6.00 per share.
How do I buy shares of Hillstream BioPharma?: Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HILS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial